Healios KK (HLOSF)
0.9804
0.00 (0.00%)
USD |
OTCM |
May 23, 16:00
Healios Enterprise Value: 62.31M for May 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 23, 2024 | 62.31M |
| May 22, 2024 | 62.31M |
| May 21, 2024 | 62.31M |
| May 20, 2024 | 62.31M |
| May 17, 2024 | 60.92M |
| May 16, 2024 | 63.48M |
| May 15, 2024 | 63.48M |
| May 14, 2024 | 63.48M |
| May 13, 2024 | 63.44M |
| May 10, 2024 | 63.44M |
| May 09, 2024 | 63.44M |
| May 08, 2024 | 63.44M |
| May 07, 2024 | 63.44M |
| May 06, 2024 | 63.44M |
| May 03, 2024 | 63.44M |
| May 02, 2024 | 63.44M |
| May 01, 2024 | 63.44M |
| April 30, 2024 | 63.44M |
| April 29, 2024 | 63.44M |
| April 26, 2024 | 63.44M |
| April 25, 2024 | 63.44M |
| April 24, 2024 | 58.66M |
| April 23, 2024 | 58.66M |
| April 22, 2024 | 58.66M |
| April 19, 2024 | 58.66M |
| Date | Value |
|---|---|
| April 18, 2024 | 58.66M |
| April 17, 2024 | 58.66M |
| April 16, 2024 | 58.66M |
| April 15, 2024 | 58.66M |
| April 12, 2024 | 58.66M |
| April 11, 2024 | 58.66M |
| April 10, 2024 | 58.66M |
| April 09, 2024 | 58.66M |
| April 08, 2024 | 58.66M |
| April 05, 2024 | 58.66M |
| April 04, 2024 | 58.66M |
| April 03, 2024 | 58.66M |
| April 02, 2024 | 58.66M |
| April 01, 2024 | 58.66M |
| March 31, 2024 | 58.66M |
| March 28, 2024 | 68.39M |
| March 27, 2024 | 68.39M |
| March 26, 2024 | 68.39M |
| March 25, 2024 | 68.39M |
| March 22, 2024 | 68.39M |
| March 21, 2024 | 68.39M |
| March 20, 2024 | 68.39M |
| March 19, 2024 | 68.39M |
| March 18, 2024 | 68.39M |
| March 15, 2024 | 68.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
54.28M
Minimum
Feb 06 2024
1.085B
Maximum
Aug 14 2023
775.29M
Average
799.86M
Median
Jun 30 2022
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co Ltd | 69.74B |
| Nxera Pharma Co Ltd | 937.44M |
| PeptiDream Inc | 1.524B |
| AnGes Inc | 59.01M |
| SanBio Co Ltd | 238.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.33M |
| Revenue (Quarterly) | 0.0674M |
| Total Expenses (Quarterly) | 7.135M |
| EPS Diluted (Quarterly) | -0.1957 |
| Profit Margin (Quarterly) | -24.24K% |
| Earnings Yield | -51.60% |
| Normalized Earnings Yield | -51.60 |